$108.26
0.09% yesterday
Nasdaq, Nov 12, 10:00 pm CET
ISIN
US45337C1027
Symbol
INCY

Incyte Stock price

$108.26
+23.53 27.77% 1M
+47.41 77.91% 6M
+39.19 56.74% YTD
+27.68 34.35% 1Y
+31.17 40.43% 3Y
+25.94 31.51% 5Y
+4.06 3.90% 10Y
+103.27 2,069.54% 20Y
Nasdaq, Closing price Wed, Nov 12 2025
+0.10 0.09%
ISIN
US45337C1027
Symbol
INCY
Industry

New AI Insights on Incyte Insights AI Insights on Incyte

How does the company make money?
Who are the company’s main competitors?

Key metrics

Basic
Market capitalization
$21.3b
Enterprise Value
$18.4b
Net debt
positive
Cash
$2.9b
Shares outstanding
196.1m
Valuation (TTM | estimate)
P/E
18.3 | 15.5
P/S
4.4 | 4.2
EV/Sales
3.8 | 3.6
EV/FCF
15.3
P/B
4.6
Financial Health
Equity Ratio
63.3%
Return on Equity
1.0%
ROCE
25.2%
ROIC
37.8%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$4.8b | $5.1b
EBITDA
$1.3b | $1.7b
EBIT
$1.3b | $1.5b
Net Income
$1.2b | $1.4b
Free Cash Flow
$1.2b
Growth (TTM | estimate)
Revenue
18.1% | 19.3%
EBITDA
2,907.2% | 1,164.4%
EBIT
6,374.0% | 1,260.6%
Net Income
3,559.4% | 4,088.1%
Free Cash Flow
3,806.8%
Margin (TTM | estimate)
Gross
93.5%
EBITDA
26.6% | 33.8%
EBIT
26.1%
Net
24.7% | 27.0%
Free Cash Flow
24.9%
More
EPS
$5.9
FCF per Share
$6.1
Short interest
6.8%
Employees
3k
Rev per Employee
$1.6m
Show more

Is Incyte a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,031 stocks worldwide.

Incyte Stock Analysis

Unlock Scores for Free

Analyst Opinions

33 Analysts have issued a Incyte forecast:

15x Buy
45%
17x Hold
52%
1x Sell
3%

Analyst Opinions

33 Analysts have issued a Incyte forecast:

Buy
45%
Hold
52%
Sell
3%

Financial data from Incyte

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
4,813 4,813
18% 18%
100%
- Direct Costs 314 314
16% 16%
7%
4,499 4,499
18% 18%
93%
- Selling and Administrative Expenses 1,313 1,313
10% 10%
27%
- Research and Development Expense 1,905 1,905
26% 26%
40%
1,281 1,281
2,907% 2,907%
27%
- Depreciation and Amortization 25 25
8% 8%
1%
EBIT (Operating Income) EBIT 1,256 1,256
6,374% 6,374%
26%
Net Profit 1,189 1,189
3,559% 3,559%
25%

In millions USD.

Don't miss a Thing! We will send you all news about Incyte directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Incyte Stock News

Neutral
Seeking Alpha
3 days ago
Incyte Corporation ( INCY ) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 10, 2025 10:00 AM EST Company Participants William Meury - CEO, President & Director Pablo Cagnoni - President and Head of Research & Development Conference Call Participants Michael Schmidt - Guggenheim Securities, LLC, Research Division Presentation Michael Schmidt Guggenheim Securities, LLC...
Neutral
Business Wire
7 days ago
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte's Moments of Clarity Program Expands to Highlight Powerful Patient Stories in Vitiligo and Pediatric Eczema.
Positive
Investors Business Daily
7 days ago
No single month beats November for S&P 500 stock market performance. And a handful of stocks are already taking off.
More Incyte News

Company Profile

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Head office United States
CEO Herve Hoppenot
Employees 2,617
Founded 1991
Website www.incyte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today